» Articles » PMID: 37268887

A Mixed-effects Stochastic Model Reveals Clonal Dominance in Gene Therapy Safety Studies

Overview
Publisher Biomed Central
Specialty Biology
Date 2023 Jun 2
PMID 37268887
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mathematical models of haematopoiesis can provide insights on abnormal cell expansions (clonal dominance), and in turn can guide safety monitoring in gene therapy clinical applications. Clonal tracking is a recent high-throughput technology that can be used to quantify cells arising from a single haematopoietic stem cell ancestor after a gene therapy treatment. Thus, clonal tracking data can be used to calibrate the stochastic differential equations describing clonal population dynamics and hierarchical relationships in vivo.

Results: In this work we propose a random-effects stochastic framework that allows to investigate the presence of events of clonal dominance from high-dimensional clonal tracking data. Our framework is based on the combination between stochastic reaction networks and mixed-effects generalized linear models. Starting from the Kramers-Moyal approximated Master equation, the dynamics of cells duplication, death and differentiation at clonal level, can be described by a local linear approximation. The parameters of this formulation, which are inferred using a maximum likelihood approach, are assumed to be shared across the clones and are not sufficient to describe situation in which clones exhibit heterogeneity in their fitness that can lead to clonal dominance. In order to overcome this limitation, we extend the base model by introducing random-effects for the clonal parameters. This extended formulation is calibrated to the clonal data using a tailor-made expectation-maximization algorithm. We also provide the companion  package RestoreNet, publicly available for download at https://cran.r-project.org/package=RestoreNet .

Conclusions: Simulation studies show that our proposed method outperforms the state-of-the-art. The application of our method in two in-vivo studies unveils the dynamics of clonal dominance. Our tool can provide statistical support to biologists in gene therapy safety analyses.

Citing Articles

Parameter inference for stochastic reaction models of ion channel gating from whole-cell voltage-clamp data.

Del Core L, Mirams G Philos Trans A Math Phys Eng Sci. 2025; 383(2292):20240224.

PMID: 40078146 PMC: 11904632. DOI: 10.1098/rsta.2024.0224.


Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations.

Yoon J, Schindler J, Loperfido M, Baricordi C, DeAndrade M, Jacobs M Mol Ther. 2024; 32(11):3847-3864.

PMID: 39295144 PMC: 11573599. DOI: 10.1016/j.ymthe.2024.09.024.


Scalable inference of cell differentiation networks in gene therapy clonal tracking studies of haematopoiesis.

Del Core L, Pellin D, Wit E, Grzegorczyk M Bioinformatics. 2023; 39(10).

PMID: 37774002 PMC: 10585354. DOI: 10.1093/bioinformatics/btad605.

References
1.
Friedmann T, Roblin R . Gene therapy for human genetic disease?. Science. 1972; 175(4025):949-55. DOI: 10.1126/science.175.4025.949. View

2.
Bryder D, Rossi D, Weissman I . Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol. 2006; 169(2):338-46. PMC: 1698791. DOI: 10.2353/ajpath.2006.060312. View

3.
Kustikova O, Wahlers A, Kuhlcke K, Stahle B, Zander A, Baum C . Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood. 2003; 102(12):3934-7. DOI: 10.1182/blood-2003-05-1424. View

4.
Fehse B, Kustikova O, Bubenheim M, Baum C . Pois(s)on--it's a question of dose. Gene Ther. 2004; 11(11):879-81. DOI: 10.1038/sj.gt.3302270. View

5.
Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z . Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 2005; 105(11):4235-46. DOI: 10.1182/blood-2004-11-4535. View